PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24081881-7	2013	Protein levels and the ROS-producing activity of Nox4 were increased in the endoplasmic reticulum (ER), but not in mitochondria, in response to GD.	Gadolinium	144-146	NADPH oxidase 4	Mus musculus	49-53	
33615889-0	2021	Overlapping roles of NADPH Oxidase 4 (Nox4) for diabetic and gadolinium-based contrast agent-induced systemic fibrosis.	Gadolinium	61-71	NADPH oxidase 4	Mus musculus	21-36	
33615889-0	2021	Overlapping roles of NADPH Oxidase 4 (Nox4) for diabetic and gadolinium-based contrast agent-induced systemic fibrosis.	Gadolinium	61-71	NADPH oxidase 4	Mus musculus	38-42	
33615889-4	2021	We examined the role of NADPH oxidase 4 (Nox4) in gadolinium-induced systemic disease.	Gadolinium	50-60	NADPH oxidase 4	Mus musculus	24-39	
33615889-6	2021	Nox4-deficient mice were randomized to experimental diabetes and gadolinium-based contrast agent treatment.	Gadolinium	65-75	NADPH oxidase 4	Mus musculus	0-4	
33615889-9	2021	Deletion of Nox4 abrogated both skin and renal pathology, whether from diabetes or gadolinium-based contrast agent treatment.	Gadolinium	83-93	NADPH oxidase 4	Mus musculus	12-16	
33615889-10	2021	These discoveries demonstrate the importance of Nox4 in gadolinium-based contrast agent- and diabetes-induced fibrosis.	Gadolinium	56-66	NADPH oxidase 4	Mus musculus	48-52	
24081881-8	2013	Selective knockdown of Nox4, but not Nox2, or selective reduction of ROS in the ER with ER-targeted catalase, but not mitochondria-targeted perioxiredoxin 3, abrogated GD-induced autophagy.	Gadolinium	168-170	NADPH oxidase 4	Mus musculus	23-27